Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Survey on perception and knowledge of over-diagnosis and over treatment in glaucoma among Spanish ophthalmologists.

Archivos de la Sociedad Espanola de Oftalmologia·2025

Same author

Reporting serious incidents in medical devices used in glaucoma surgery. Proposing ideas (III).

Archivos de la Sociedad Espanola de Oftalmologia·2025

Same author

Atypical presentation of type 1 neovascularization with aneurysmal dilations in a young female.

Archivos de la Sociedad Espanola de Oftalmologia·2024

Same author

About the need to update the official program of ophthalmology specialty in Spain.

Archivos de la Sociedad Espanola de Oftalmologia·2024

Same author

Treatment of periorbital hyperpigmentation using light devices.

Archivos de la Sociedad Espanola de Oftalmologia·2023

Same author

Specific training areas: At last, subspeciality title in Spain.

Archivos de la Sociedad Espanola de Oftalmologia·2022

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

[New developments in glaucoma medical treatment].

F J Muñoz-Negrete¹, M Pérez-López, H R Won Kim

¹Sección de Glaucoma del Servicio de Oftalmología del Hospital Ramón y Cajal, España. franciscojmunoz@telefonica.net

Archivos De La Sociedad Espanola De Oftalmologia

|November 11, 2009

Summary

This summary is machine-generated.

Glaucoma treatment is advancing with improved existing drugs and novel molecules. New research explores calcium channel blockers, endothelin antagonists, and Rho-kinase inhibitors for better glaucoma management.

More Related Videos

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Related Experiment Videos

Last Updated: Jun 18, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

Ophthalmology
Pharmacology

Context:

Glaucoma treatment research is rapidly evolving.
Focus on enhancing existing therapies and discovering new drug classes.

Purpose:

To review recent advancements in medical glaucoma treatment.
To highlight novel therapeutic strategies and drug candidates.

Summary:

Improvements in commercial glaucoma drugs include better preservatives (e.g., sofZIA) and preservative-free options (e.g., tafluprost).
New fixed-combination drugs aim to improve patient compliance.
Emerging therapeutic targets include calcium channel blockers (e.g., lomerizine, flunarizine), endothelin 1 antagonists (e.g., sulfisoxazole), renin-angiotensin system modulators (e.g., angiotensin (1-7), olmesartan), Rho-kinase inhibitors, and topical mifepristone for steroid-induced ocular hypertension.

Impact:

These developments promise improved local tolerance, enhanced therapeutic compliance, and novel treatment options for glaucoma.
Research into new drug classes offers potential for more targeted and effective glaucoma management.